CELLSIGHT TECHNOLOGIES, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cellsighttech.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- CellSight Technologies, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06107374
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Test-retest Evaluation of [18F]F-AraG PET
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: [18F]F-ARAG PET
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- CellSight Technologies, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06084806
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Imaging Immune Activation in COVID-19
- Conditions
- SARS-CoV InfectionCovid19
- Interventions
- Drug: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- CellSight Technologies, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04815096
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- CellSight Technologies, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04726215
- Locations
- 🇺🇸
Palo Alto Veterans Institute of Research, Palo Alto, California, United States
🇺🇸Sutter Cancer Center, Sacramento, California, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
- Conditions
- Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- CellSight Technologies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04260256
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
- Prev
- 1
- 2
- Next